Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The group usually releases upbeat results with huge surprise rates.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 166.72 USD
Weaknesses
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ALLERGAN PLC17.69%65 346
JOHNSON & JOHNSON0.53%380 898
PFIZER19.44%256 467
NOVARTIS-0.56%216 108
ROCHE HOLDING LTD.-4.65%210 186
MERCK AND COMPANY25.79%188 241
AMGEN17.99%132 756
ABBOTT LABORATORIES20.03%120 680
ELI LILLY AND COMPANY25.20%113 918
SANOFI3.92%110 120
BRISTOL-MYERS SQUIBB COMPAN..-0.78%100 768
GLAXOSMITHKLINE12.35%97 753
ASTRAZENECA8.81%92 763
NOVO NORDISK A/S-10.76%90 203
BAYER-25.92%83 311
CELGENE CORPORATION-15.39%62 107
More Results
Financials ($)
Sales 2018 15 523 M
EBIT 2018 7 411 M
Net income 2018 -1 186 M
Debt 2018 23 063 M
Yield 2018 1,44%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,70x
EV / Sales 2019 5,46x
Capitalization 65 346 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ALLERGAN PLC
Duration : Period : Day
Allergan plc Technical Analysis Chart | MarketScreener
Duration : Period : Week
Allergan plc Technical Analysis Chart | MarketScreener